Apollomics Reports Full Year 2025 Results and Plans 2027 IND Submission for Vebreltinib

Apollomics Inc. reported full-year 2025 financial results, highlighted by a significant strategic turnaround and a 64% reduction in operating expenses. Revenue for 2025 reached $8.5 million, primarily driven by an upfront licensing payment from LaunXP for vebreltinib in Asia. Net loss narrowed substantially to $10.9 million ($7.57 per share) from $53.9 million ($52.80 per share) in 2024. Research and development expenses decreased to $5.5 million as the company streamlined operations. On the clinical front, Apollomics is prioritizing the global development of vebreltinib (APL-101), its c-MET inhibitor. The company plans to submit an IND application for accelerated approval in second-line NSCLC with c-MET amplification in the first half of 2027. Vebreltinib is already approved in China for three indications. Additionally, the company successfully resolved legacy litigation and raised $4.1 million via a PIPE financing in September 2025. As of December 31, 2025, cash and equivalents stood at approximately $3.3 million.